RxDoctor Payments DataLook up a doctor →

Dragos Zanchi, MD

Pulmonary Disease · Brandon, FLNPI 1922068550

Payments from drug & device makers

$1,025,487in general payments, 2019–2025

Across 1,405 payments — averaging $729.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$436K
  • Harmony Biosciences LLC$180K
  • Alkermes, Inc.$137K
  • Takeda Pharmaceuticals U.S.A., Inc.$122K
  • AstraZeneca$49K
  • Boehringer Ingelheim$33K
  • plus $67K from 54 others

What the payments were for

  • Consulting fees$2501%
  • Speaking & faculty fees$16,00035%
  • Travel & lodging$7012%
  • Food & beverage$19,23742%
  • Education$9,20320%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Jazz Pharmaceuticals Inc.291$436,080
Harmony Biosciences LLC78$180,424
Alkermes, Inc.82$136,902
Takeda Pharmaceuticals U.S.A., Inc.67$122,128
AstraZeneca148$48,872
Boehringer Ingelheim59$33,495
Romark Laboratories, LC1$21,075
Sanofi US Services Inc.1$12,731
GSK241$10,075
Intuitive Surgical16$10,009
Boehringer Ingelheim International GmbH34$4,366
Grifols USA, LLC37$864
Sanofi23$639
Regeneron Healthcare Solutions, Inc.21$525
Amgen24$478
Insmed, Inc.17$442
Inspire Medical Systems, Inc.4$419
Mylan Specialty L.p.17$412
Eisai Inc.17$394
Philips North America LLC17$392
ANI Pharmaceuticals, Inc.12$392
Novartis19$374
Pharming Healthcare, Inc.4$318
Genentech USA, Inc.20$311
Mallinckrodt Hospital Products Inc.11$257
Regeneron3$233
Electromed, Inc.15$219
Baxter Healthcare11$208
United Therapeutics Corporation9$190
Axsome Therapeutics, Inc.7$151
Medical Device Business Services, Inc.1$148
Somnomed Inc.1$133
Circassia Inc.14$130
Advanced Respiratory, Inc6$115
Covis Pharma GmbH4$100
Galvanize Therapeutics, Inc1$98
Fujifilm Healthcare Americas Corporation1$95
Sunovion Pharmaceuticals Inc.9$94
Phadia US Inc.5$91
Teva Pharmaceuticals USA, Inc.4$89
Bayer4$79
Arbor Pharmaceuticals, Inc.4$76
Merck3$56
Actelion Pharmaceuticals US, Inc.3$55
Pulmonx Corporation3$55
Genentech, Inc.1$47
Paratek Pharmaceuticals, Inc.3$42
Verona Pharma, Inc.2$42
Lilly USA, LLC2$41
3b Medical, Inc.3$39
Almatica Pharma LLC2$38
Resmed Corp2$38
Nabriva Therapeutics, PLC3$38
Avanir Pharmaceuticals, Inc.1$35
Shield Therapeutics Inc2$35
Alk-abello, Inc1$33
Vapotherm Inc1$32
Ambu Inc.1$31
Optinose US, Inc.2$30
Inogen, Inc.1$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,025,487 in reported general payments places this provider in the 95th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$539,387
Medicare patients
715
Services billed
11,066

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter1,545$1,209,464
Prolastin CAlpha-1-Proteinase Inhibitor79$964,487
OfevNintedanib Esylate64$854,046
Breztri AerosphereBudesonide/Glycopyr/Formoterol570$422,150
Spiriva RespimatTiotropium Bromide570$361,054
GlassiaAlpha-1-Proteinase Inhibitor20$282,442
SymbicortBudesonide/Formoterol Fumarate817$228,543
Spiriva HandihalerTiotropium Bromide194$166,253
Breo ElliptaFluticasone/Vilanterol294$148,319
WakixPitolisant Hcl12$95,217
TezspireTezepelumab-Ekko20$89,426
Dupixent PenDupilumab23$85,576
XolairOmalizumab14$78,185
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr134$75,354
Incruse ElliptaUmeclidinium Bromide168$70,033

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$10,075$1,503,1692,141 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat$33,495$1,295,661767 claims
Grifols USA, LLCProlastin C$864$964,48779 claims
AstraZenecaBreztri Aerosphere, Symbicort, Tezspire$48,872$740,1191,407 claims
Takeda Pharmaceuticals U.S.A., Inc.Glassia$122,128$282,44220 claims
Harmony Biosciences LLCWakix$180,424$95,21712 claims
Genentech, Inc.Xolair$47$78,18514 claims
Lilly USA, LLCMounjaro$41$21,06722 claims
MerckDulera$56$3,53411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Brandon

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →